Glucagon-like peptide 2

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 4, 2001, Pages 1759-1764

  Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 2; PROGLUCAGON;

AMINO ACID ANALYSIS; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROTECTION; CRYPT CELL; ENDOCRINE CELL; HUMAN; INTESTINE EPITHELIUM; INTESTINE INJURY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SEPTICEMIA; SHORT BOWEL SYNDROME;

AMINO ACID SEQUENCE; ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, GLUCAGON;

EID: 0035037843     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.4.1759     Document Type: Article

References (81)

1. The glucagon-like peptides
2. The glucagon-like peptides
3. Enteroglucagon
4. The glucagon-like peptides
5. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
6. Hamster preproglucagon contains the sequence of glucagon and two related peptides
7. Exon duplication and divergence in the human preproglucagon gene
8. Glucagon gene sequence: Four of the six exons encode separate functional domains of rat pre-proglucagon
9. Pre-proglucagon messenger ribonucleic acid: Nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid
10. Structure of the human glucagon gene
11. Trout and chicken proglucagon: Alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2
12. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
13. Role of prohormone convertases in the tissue-specific processing of proglucagon
14. Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine
15. Structure, measurement, and secretion of human glucagon-like peptide-2
16. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase
17. Molecular biology of gastrointestinal peptides and growth factors: Relevance to intestinal adaptation
18. The hormonal pattern of intestinal adaptation [a major role for enteroglucagon]
19. Gut hormone release after intestinal resection
20. Evidence for a humoral mechanism after small intestinal resection
21. Hyperenteroglucagonaemia and small intestinal mucosal growth after colonic perfusion of glucose in rats
22. Humoral regulation of intestinal adaptation
23. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
24. Glucagonoma syndrome demonstrating giant duodenal villi
25. Induction of intestinal epithelial proliferation by glucagon-like peptide 2
26. Glucagon gene expression in vertebrate brain
27. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine
28. Identical mRNA for preproglucagon in pancreas and gut
29. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
30. Nutrient-independent increases in proglucagon and ornithine decarboxylase messenger RNAs after jejunoileal resection
31. Effects of fasting, refeeding and intraluminal triglyceride on proglucagon expression in jejunum and ileum
32. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats
33. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats
34. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)
35. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2
36. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans
37. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: How much is enough?
38. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: Effects of dietary fibre
39. Ileal proglucagon gene expression in the rat: Characterization in intestinal adaptation using in situ hybridization
40. Ileal glucagon gene expression: Ontogeny and response to massive small bowel resection
41. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection
42. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth
43. All products of proglucagon are elevated in plasma from uremic patients
44. Renal catabolism of human glucagon-like peptides 1 and 2
45. Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in the rat
46. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
47. Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV
48. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
49. CD26, let it cut or cut it down
50. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice
51. Intestinal growth is associated with elevated levels of glucagon-like peptide-2 in diabetic rats
52. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
53. Impaired meal-stimulated glucagon-like peptide-2 response in ileal resected short bowel patients with intestinal failure
54. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
55. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2
56. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs
57. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport
58. Up-regulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
59. Glucagon-like peptide-2 enhances epithelial barrier function of both transcellular and paracellular pathways in the mouse
60. Intestinal growth-promoting properties of glucagon-like peptide 2 in mice
61. Biological determinants of intestinotrophic properties of GLP-2 in vivo
62. Prevention of parenteral nutrition-induced gut hyoplasia by coinfusion of glucagon-like peptide-2
63. Intestinal response to growth factors administered alone or in combination with h[Gly2]-glucagon-like peptide 2
64. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2
65. Glucagon-like peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo
66. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake
67. Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal- related homeobox protein-2 gene expression
68. GLP-2 augments the adaptive response to massive intestinal resection in rat
69. Hormonal therapy for short bowel syndrome
70. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis
71. Glucagon-like peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
72. Human [Gly2]-GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
73. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2
74. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine
75. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis
76. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
77. Structural determinants for activity of glucagon-like peptide-2
78. Enteroendocrine localization of GLP-2 receptor expression
79. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway
80. Glucagon-like peptide-2 (GLP-2) reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor
81. Treatment of short bowel patients with glucagon-like peptide-2 (GLP-2), a newly discovered intestinotrophic, anti-secretory, and transit-modulating peptide